The present invention provides ligands capable of binding to prion protein, such as anti-prion protein antibodies and antigen-binding fragment thereof, for the prevention and/or treatment of synucleinopathies, such as Parkinson's disease. The present invention also provides pharmaceutical compositions comprising such ligands and methods for treating synucleinopathies or for reducing the uptake of ±-synuclein fibrils.
Ligands binding to prion protein for use in the treatment of synucleinopathies / Legname, G.. - (2017 May 23).
|Titolo:||Ligands binding to prion protein for use in the treatment of synucleinopathies|
|Data di deposito:||2017-05-23|
|Numero di deposito:||EP20170425051 20170523|
|Appare nelle tipologie:||6.1 Patent|